Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...
His influence is partly the result of a very online political establishment, and partly thanks to a right-leaning media that is hostile to Keir Starmer’s Labour government. By Mark Landler The ...
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback